Stock exchange news | Navamedic

Read the latest news directly from the market.

Navamedic ASA has entered into a market making agreement with Norne Securities AS

Oslo, 11. November 2021 – Navamedic ASA (OSE: NAVA) today announces it has entered into a market making agreement with Read more

Navamedic ASA: Q3 2021 financial results

“Our portfolio of specialty pharma and consumer health products continue to grow with particularly strong performance for the obesity medicine Read more

Navamedic ASA: Invitation to 2021 Third quarter presentation

Navamedic ASA invites you to a presentation of the 2021 third quarter results on Thursday, November 4th at 08.45 CET. The presentation Read more

Navamedic ASA extends exclusive distribution rights for Mysimba in the Nordics

Mysimba® is the first obesity treatment of its kind, combining both an oral medicin with a digital and custom-made patient Read more

Navamedic ASA receives approval for conditional reimbursement for Mysimba® in Finland

Mysimba® is the first obesity treatment of its kind, combining both an oral medicin with a digital and custom-made patient Read more

Navamedic ASA: Q2 and first half 2021 financial results

“We continue to deliver rapid growth for our specialty pharma product Mysimba and consumer health products Alflorex and ThermaCare. In Read more

Navamedic ASA: Invitation to 2021 Second quarter presentation

Navamedic ASA invites you to a presentation of the 2021 second quarter results on Friday, August 13th at 08.30 CET. The Read more

Treating the side-effects of the pandemic

Musculoskeletal pain is often a result of muscle tension and overexertion, psychological stress or working postures, often in combination with Read more

Subscribe to stock exhange news